{"id":"tucidinostat-azacitidine-combined-with-chop","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1489","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tucidinostat works by inhibiting histone deacetylases, which can lead to changes in gene expression. Azacitidine, on the other hand, works by inhibiting DNA methyltransferases, leading to hypomethylation of DNA. CHOP is a combination chemotherapy regimen consisting of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone, which targets rapidly dividing cancer cells.","oneSentence":"Tucidinostat is a histone deacetylase inhibitor, while Azacitidine is a hypomethylating agent, and CHOP is a chemotherapy regimen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:05.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT05075460","phase":"PHASE3","title":"Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"T-cell Lymphoma","enrollment":107},{"nctId":"NCT05678933","phase":"PHASE3","title":"AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":"Peripheral T-cell Lymphoma Targeted Therapy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tucidinostat, Azacitidine combined with CHOP","genericName":"Tucidinostat, Azacitidine combined with CHOP","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tucidinostat is a histone deacetylase inhibitor, while Azacitidine is a hypomethylating agent, and CHOP is a chemotherapy regimen. Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}